News

Under the terms of the agreement, Aeterna Zentaris granted Nippon Kayaku an exclusive license to develop and market ozarelix for all potential oncological indications in Japan. In return,

This phase I study is designed to assess the safety, tolerability and preliminary efficacy of sphingosome encapsulated vinorelbine in patients with advanced solid tumors. Hana is developing this

The researchers reported in The Journal of Neurophysiology that using two ampakine drugs, which are currently in preclinical development by Cortex Pharmaceuticals, reversed age-related declines in cognitive functions

This novel approach to therapy is intended to provide the same efficacy as the currently marketed nebulizer product, but with a lower dose delivered in less time. The

Exubera, co-developed by Pfizer and Nektar Therapeutics, is approved for the treatment of type 1 and type 2 diabetes. It represents an advance in the treatment of the

Recently SIGA-246 successfully completed its initial human safety clinical trial. “The NIH has been a great supporter of our efforts to develop SIGA-246 during the past two years.

In the trial, Ceftaroline was compared with the current standard therapy in 100 patients at 24 study sites worldwide. The clinical cure rate was 96.8% for subjects treated

PTI-202 is the second such drug to enter clinical development under the collaboration. The first drug to be developed was Remoxy, an abuse-resistant oxycodone which is currently in

The regulator said that the counterfeit Lipitor was originally removed from the market in the UK in July 2005, but was recently found there again in a pharmacy.